Concert Pharma Initiates Phase 1 Single-Ascending Dose Trial of CTP-692 as an Adjunctive Treatment…
Concert Pharmaceuticals announced that it has initiated the second Phase 1 clinical trial with CTP-692, a novel deuterium-modified form of D-serine being developed as an adjunctive…
Read More...
Read More...